Cardiovascular and Renal Protection in Type 2 Diabetes

Introduction to Semaglutide Formulations

The American Diabetes Association recommends injectable semaglutide as a first-line therapy for patients with or at high risk for atherosclerotic cardiovascular disease, heart failure, or kidney disease, due to its proven cardiovascular benefits 1
Injectable semaglutide has demonstrated mortality reduction and cardiovascular benefits, while oral semaglutide only showed non-inferiority for cardiovascular outcomes 2

Injectable semaglutide reduced cardiovascular events as a primary outcome compared with placebo in patients with established cardiovascular disease 2
The American College of Cardiology and American Heart Association support the use of GLP-1 RAs with proven cardiovascular benefits, such as injectable semaglutide, for patients with established cardiovascular disease or high cardiovascular risk 1

For patients with diabetic kidney disease, injectable semaglutide is undergoing dedicated renal outcome trials, while oral semaglutide lacks this evidence base 2

Choose injectable semaglutide when a patient has established cardiovascular disease or high cardiovascular risk, or when a patient has diabetic kidney disease 2, 1
Consider injectable semaglutide for maximum glycemic efficacy and greater weight loss, as it produces significantly greater weight loss than oral semaglutide 3

Injectable semaglutide can be administered once weekly at any time of day without food restrictions, making it a more convenient option for patients 1

Injectable semaglutide reduced major adverse cardiovascular events by 26% (HR 0.74 [95% CI 0.58–0.95]; P < 0.001) in the SUSTAIN-6 trial, demonstrating cardiovascular superiority 4
Oral semaglutide only demonstrated cardiovascular non-inferiority to placebo (HR 0.79 [95% CI 0.57–1.11]; P < 0.001 for noninferiority) in the PIONEER-6 trial—it did NOT show superiority 4
Both formulations share similar gastrointestinal side effects (primarily nausea and diarrhea) 4

The SUSTAIN-6 trial enrolled 3,297 patients with type 2 diabetes at high cardiovascular risk, randomized to once-weekly subcutaneous semaglutide (0.5 mg or 1.0 mg) or placebo for 2 years, demonstrating a primary composite outcome of cardiovascular death, nonfatal MI, or nonfatal stroke in 6.6% of semaglutide patients versus 8.9% of placebo patients (HR 0.74 [95% CI 0.58–0.95]; P < 0.001 for superiority) 5
Cardiovascular deaths were significantly reduced: 4.7% with semaglutide versus 6.0% with placebo 5
More patients discontinued treatment due to adverse events, mainly gastrointestinal 5
The PIONEER-6 trial enrolled 3,183 patients with type 2 diabetes and high cardiovascular risk, followed for a median of 15.9 months, demonstrating non-inferiority of oral semaglutide to placebo for the primary composite outcome (HR 0.79 [95% CI 0.57–1.11]; P < 0.001 for noninferiority) 5

No cited facts are available for this section, however, the following uncited recommendation is made: The American Diabetes Association recommends injectable semaglutide as a first-line therapy for patients with or at high risk for atherosclerotic cardiovascular disease, heart failure, or kidney disease